BioNTech SE stock dips as CEO share sale and trial setback temper lung cancer optimism

BioNTech SE stock (ISIN US09075V1026) traded around USD 95.83 on Nasdaq as of September 19, 2026, reflecting a recent pullback that coincides with CEO Ugur Sahin’s sale of 64,000 shares and mixed clinical-news signals for the biotech company.

CEO share sale and rating backdrop

According to StockTitan on September 18, 2026, BioNTech CEO and major shareholder Ugur Sahin executed pre-arranged Rule 10b5-1 sales totaling 64,000 ordinary shares on September 17 and September 18, 2026, at weighted-average prices of USD 98.60 and USD 96.22 per share respectively under a trading plan established on June 3, 2026.

The same filing shows that after these transactions, an entity associated with Sahin, Medine GmbH, still holds 39,218,111 ordinary shares indirectly attributed to him, illustrating that the disposals represent a small fraction of his overall economic exposure to BioNTech SE.StockTitan

As MarketBeat reported on September 18, 2026, Sahin’s sales were executed near USD 102.85 per share in one transaction and came against a backdrop where BioNTech shares recently traded at around USD 96.06 and where analysts collectively assign the stock an average “Moderate Buy” rating with a consensus target price of USD 126.00.

Fundamentals: revenue drop and losses in FY26

Per Nasdaq data compiled on Yahoo Finance as of September 19, 2026, BioNTech posted Q1 fiscal year 2026 revenue of USD 118.1 million, accompanied by a net loss of USD 531.9 million and a GAAP earnings per share of minus USD 2.22, implying a profit margin of around minus 450.38 percent for that quarter.

Compared with the company’s pandemic-era results, this level of revenue represents a sharp contraction; MarketBeat notes a year-over-year revenue decline of about 59.5 percent in recent quarterly figures, underlining how the normalization of Covid-19 vaccine demand has weighed on the company’s top line.

The earnings profile is equally challenging for investors: with trailing twelve-month GAAP EPS standing at around minus USD 7.74 as of September 19, 2026, BioNTech SE is currently loss-making, and its profitability hinges on scaling its oncology pipeline and other vaccine initiatives beyond Covid-19.Yahoo Finance

Pipeline signals: strength in lung cancer, risk in colorectal cancer

On the positive side, BioNTech recently highlighted promising data for its investigational drug gotistobart in non-small cell lung cancer. According to Panabee on September 19, 2026, updated stage 1 results from the PRESERVE-003 Phase 3 trial showed that gotistobart achieved a median overall survival of 18.5 months compared with 10.0 months for standard-of-care chemotherapy in previously treated squamous non-small cell lung cancer patients.

This early-stage outcome implies that patients receiving gotistobart lived about 8.5 months longer than those on conventional therapy in the analyzed cohort, and the ongoing pivotal stage 2 portion of the trial is designed to confirm these survival benefits in a larger population.Panabee

Counterbalancing this favorable lung cancer signal, BioNTech also recently faced a setback in colorectal cancer. As MSN reported on September 18, 2026, BioNTech and its partner Genentech, part of Roche, terminated a Phase 2 study of the mRNA vaccine candidate autogene cevumeran for colorectal cancer after the company’s August 28, 2026 update indicated insufficient efficacy.

The MSN analysis characterizes the termination of the Phase 2 autogene cevumeran study as a legitimate cause for investor concern regarding BioNTech’s broader oncology strategy, while stressing that it does not fundamentally undermine the company’s long-term prospects given its diversified pipeline and technology platform.MSN

Governance update: new auditor proposal for 2027

Beyond clinical and financial developments, BioNTech has also moved to adjust its external audit arrangements. According to a current report filed with the U.S. Securities and Exchange Commission and summarized by StockTitan, BioNTech’s Supervisory Board approved the appointment of KPMG AG Wirtschaftsprüfungsgesellschaft as the company’s independent auditor for the financial year ending December 31, 2027 on September 18, 2026.

The filing notes that this appointment remains subject to election by shareholders at the upcoming Annual General Meeting, indicating that investors will have an opportunity to vote on the proposed change in auditor as part of BioNTech’s broader corporate governance framework.StockTitan

BioNTech SE stock price and trading context

Per Nasdaq data from Yahoo Finance, BioNTech SE stock recently changed hands at USD 95.83 on Nasdaq at 11:37 a.m. Eastern Time on September 18, 2026, down USD 2.83 or about 2.87 percent on the day, with a trailing 52-week range between roughly USD 68.35 and USD 105.80 and a market capitalization close to USD 22.0 billion as of that date.

More news and analyses on BioNTech SE stock